Medication Management

Can You Get ADHD Medication Through Telehealth? The Rules for 2026 and 2027

By Dr. Stacey Forbes, DNP, APRN, PMHNP-BC · Updated October 12, 2026

Yes, as of October 2026, you can be prescribed ADHD medication, including stimulants, through telehealth, provided the prescriber follows federal and state law. What happens after 31 December 2026 is less certain. The federal rule that allows controlled-substance prescribing by video without an in-person visit is temporary, and its permanent replacement hasn’t been published. This page sets out what is law today, what has only been proposed, and what you can do now to protect your care either way. It is general information, not legal advice.

The law underneath: an in-person visit, with exceptions

The federal Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance remotely. Once a prescriber has done that in-person evaluation, the requirement is met for that prescriber and patient. They can keep prescribing by telemedicine, as long as each prescription is for a legitimate medical purpose and follows other federal and state rules.

This matters for ADHD because the most commonly prescribed stimulants are controlled substances. On the DEA’s current list (dated 27 August 2026), amphetamine, lisdexamfetamine, and methylphenidate are all in Schedule II, the tightest category for medications that have an accepted medical use. Benzodiazepines such as alprazolam and clonazepam are Schedule IV.

What the law allows right now (through 31 December 2026)

During the COVID-19 public health emergency, the DEA temporarily waived the in-person requirement. It has extended that waiver four times since. The current version is the Fourth Temporary Extension, published in the Federal Register on 31 December 2025 (document 2025-24123). It is effective from 1 January 2026 through 31 December 2026.

Under it, any DEA-registered practitioner may prescribe Schedule II–V controlled medications over an audio-video telemedicine visit to a patient they have never seen in person. Every prescription still has to meet all other federal and state requirements. The DEA said it extended the rule to avoid a “telemedicine cliff,” an abrupt loss of access, while it finishes permanent rules.

The special registration rule: where it stands on 12 October 2026

The permanent framework the DEA has proposed is called special registration for telemedicine. Here is what is documented, with dates:

• 17 January 2025: the DEA published the proposed rule, “Special Registrations for Telemedicine and Limited State Telemedicine Registrations.” By the DEA’s count, it drew more than 6,475 comments.
• 25 August 2026: the White House Office of Information and Regulatory Affairs (OIRA) received the final rule for review (RIN 1117-AB40).
• 12 October 2026: OIRA still lists the rule as pending review. No final rule has been published in the Federal Register, and the final text is not public.

Because the final text isn’t public, nobody outside government knows exactly what it says. The proposal gives some idea of the DEA’s thinking. For Schedule II drugs such as stimulants, it proposed:

• a separate “Advanced Telemedicine Prescribing Registration,” limited to certain specialized physicians and board-certified mid-level practitioners;
• that the prescriber be physically in the same state as the patient when issuing a Schedule II prescription under the special registration;
• that such telemedicine prescriptions make up less than half of the prescriber’s Schedule II prescriptions in a month;
• mandatory electronic prescribing and prescription-monitoring checks, eventually across all states.

Final rules often change after public comment. Treat these points as what was proposed in January 2025, not as what will apply in 2027.

What could change on 1 January 2027

Three outcomes are possible, and as of October 2026 none can be ruled out:

Stimulants versus non-stimulant options

The telehealth debate is about controlled substances only. Several ADHD medications are not controlled. Atomoxetine, viloxazine, and guanfacine don’t appear on the DEA’s controlled substances list, so the Ryan Haight Act’s in-person requirement doesn’t apply to them. They can be prescribed by telehealth under ordinary standards of care.

That doesn’t make non-stimulants a fallback or a second-best choice. They work differently, usually take longer to show their full effect, and suit some people better, for example when anxiety, sleep problems, or substance-use history makes a stimulant a poor fit. Whether a stimulant or a non-stimulant is right is a clinical decision. Regulatory convenience shouldn’t drive it. Our guide to stimulants versus non-stimulants for adults compares them, and Is ADHD Medication Right for You? covers the decision itself.

State law can be stricter

Federal rules set a floor. Each state can add its own requirements, and the law of the state where you are physically located during the visit applies. Two examples from states Willow & Stone serves:

• Florida. Florida Statute 456.47(2)(c) bars telehealth providers from prescribing Schedule II controlled substances by telehealth except for four listed purposes: treatment of a psychiatric disorder, inpatient hospital treatment, hospice care, and nursing home residents. Psychiatric care uses the first exception.
• Texas. Texas Health and Safety Code 481.0764 requires prescribers to check the state prescription monitoring database before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol. Checking it is allowed before prescribing any other controlled substance, including stimulants.

New Mexico, Alaska, Arizona, and Colorado have their own rules for telehealth and controlled substances, and we haven’t summarized them here. Your prescriber has to follow them, so ask if you have questions about your state.

Practical steps to protect your care

1. Keep your appointments. Schedule II prescriptions can’t be refilled, so every fill depends on an active relationship with your prescriber. Missed follow-ups are the most common cause of gaps.
2. One prescriber, one pharmacy. Getting controlled medications from more than one prescriber, or filling them at many pharmacies, shows up in prescription-monitoring databases and can complicate your care. Tell your prescriber about every controlled medication you take.
3. Ask now about 2027. If your care is telehealth-only, ask your prescriber what their plan is if the rules change. If an in-person evaluation becomes necessary, knowing early gives you time to schedule one.
4. Plan around shortages. As of early October 2026, the FDA drug shortage database lists current shortages of mixed amphetamine salts tablets, lisdexamfetamine, and some extended-release methylphenidate products. Call your pharmacy several days before you need a fill. If it’s out, an unfilled electronic prescription can be transferred once to another pharmacy (see switching prescribers and pharmacies).
5. Be in an approved state at each visit. Your prescriber must be licensed where you are physically located at the time of the visit, and different state rules may apply there.
6. Store and use the medication as prescribed. Keep stimulants secured, and never share them. Diverted medication is exactly what these rules are designed to prevent.

ADHD care at Willow & Stone

Willow & Stone treats adult ADHD with a whole-person evaluation that looks at sleep, nutrition, hormones, and coexisting anxiety or mood symptoms alongside focus and attention. Medication, stimulant or not, is one part of the plan when it’s clinically indicated and lawful. Dr. Stacey Forbes, a board-certified psychiatric nurse practitioner, may prescribe controlled substances in those circumstances. The practice follows the federal and state rules in effect at the time of each visit, and will tell you if an in-person visit in Arlington, Texas becomes necessary.

Telehealth is available to patients located in Texas, New Mexico, Florida, Alaska, Arizona, and Colorado. Read more in ADHD beyond stimulants and our approach to medication management, or start at the consultation page.

Common Questions

Sources & Further Reading

• Federal Register — Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (31 Dec 2025)
• Federal Register — Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule (17 Jan 2025)
• OIRA (reginfo.gov) — EO 12866 review record for the special registration final rule, RIN 1117-AB40
• DEA Diversion Control — Controlled Substances, Alphabetical Order
• Florida Statutes § 456.47 — Use of telehealth to provide services
• FDA — Drug Shortages database

This article is general education, not advice for your situation. Do not start, stop, or change a medication or supplement without talking to the clinician who prescribes it.